Steven A. Nichtberger
Net Worth
Last updated:
What is Steven A. Nichtberger net worth?
The estimated net worth of Dr. Steven A. Nichtberger is at least $4,240,486 as of 19 Oct 2022. He owns shares worth $1,627,006 as insider and has received compensation worth at least $2,613,480 in Cabaletta Bio, Inc..
What is the salary of Steven A. Nichtberger?
Dr. Steven A. Nichtberger salary is $871,160 per year as Co-Founder, Chairman, Chief Executive Officer & Pres in Cabaletta Bio, Inc..
How old is Steven A. Nichtberger?
Dr. Steven A. Nichtberger is 64 years old, born in 1961.
What stocks does Steven A. Nichtberger currently own?
As insider, Dr. Steven A. Nichtberger owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | Co-Founder, Chairman, Chief Executive Officer & Pres | 986,483 | $1.65 | $1,627,006 |
What does Cabaletta Bio, Inc. do?
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Steven A. Nichtberger insider trading
Cabaletta Bio key executives
Cabaletta Bio, Inc. executives and other stock owners filed with the SEC:
- Dr. David J. Chang M.D., M.P.H. (62) Chief Medical Officer
- Dr. Gwendolyn K. Binder (50) Executive Vice President of Science & Technology
- Dr. Steven A. Nichtberger (64) Co-Founder, Chairman, Chief Executive Officer & Pres